AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37407711 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 122
Study 37407720 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted partial nephrectomy (RAPN)
Number of subjects: 466
Study 37407852 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra I or higher
Number of subjects: 422
Study 37407852 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra ≥ II
Number of subjects: 422
Study 37407852 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra severity for elective craniotomies
Number of subjects: 422
Study 37407852 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra ≥ II for emergent craniotomies
Number of subjects: 422
Study 37407851 — intervention group
Group type: EXPERIMENTAL
Intervention: None to moderate foraminal stenosis (0-1)
Number of subjects: 437
Study 37407851 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe foraminal stenosis (2-3)
Number of subjects: 437
Study 37407851 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe foraminal stenosis
Number of subjects: 437
Study 37407950 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physical activity counseling/motivational intervention
Number of subjects: 122
Study 37407950 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Number of subjects: 122
Study 37407950 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 122
Study 37407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualization of alarm thresholds for monitoring vital signs
Number of subjects: 0
Study 37407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of novel technological features into alarm management
Number of subjects: 0
Study 37407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration among stakeholders for establishing a standard for individualization
Number of subjects: 0
Study 37407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Making alarms meaningful and trustworthy
Number of subjects: 0
Study 37408018 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy (GDHT)
Number of subjects: 34
Study 37408018 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 34
Study 37408022 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty markers including a blood-based biomarker panel
Number of subjects: 150
Study 37408022 — intervention group
Group type: COMPARATOR
Intervention: Non-frail patients
Number of subjects: 150
Study 37408022 — intervention group
Group type: COMPARATOR
Intervention: Frail patients (CFS ≥ 4)
Number of subjects: 150
Study 37408044 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subzero-balance ultrafiltration (SBUF)
Number of subjects: 20
Study 37408044 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 20
Study 37408075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/zidebactam (WCK 5222) administered under compassionate use
Number of subjects: 1
Study 37408075 — intervention group
Group type: COMPARATOR
Intervention: Polymyxins (failed treatment)
Number of subjects: 1
Study 37408298 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality headset simulating nature environment (watched videos containing nature images and sounds for 5 minutes per session, three times daily for 2 days)
Number of subjects: 131
Study 37408298 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 131
Study 37408333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, cytarabine, and dexamethasone
Number of subjects: 0
Study 37408473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Choice HIV Prevention (DCP) intervention
Number of subjects: 612
Study 37408953 — intervention group
Group type: COMPARATOR
Intervention: Standard Quitline
Number of subjects: 1944
Study 37408953 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Quitline
Number of subjects: 1944
Study 37408953 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Quitline + Social Needs Navigation
Number of subjects: 1944
Study 37408953 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Quitline + Social Needs Navigation
Number of subjects: 1944
Study 37408978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 37408999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampons (various products)
Number of subjects: 0
Study 37409159 — intervention group
Group type: EXPERIMENTAL
Intervention: GH001 (5-methoxy-N,N-dimethyltryptamine) 12 mg
Number of subjects: 16
Study 37409159 — intervention group
Group type: EXPERIMENTAL
Intervention: GH001 (5-methoxy-N,N-dimethyltryptamine) 18 mg
Number of subjects: 16
Study 37409159 — intervention group
Group type: EXPERIMENTAL
Intervention: GH001 (5-methoxy-N,N-dimethyltryptamine) individualized dosing
Number of subjects: 16
Study 37409159 — intervention group
Group type: EXPERIMENTAL
Intervention: GH001 (5-methoxy-N,N-dimethyltryptamine)
Number of subjects: 16
Study 37409229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladarixin (LDX) 400 mg twice daily for three cycles of 14 days on/14 days off
Number of subjects: 76
Study 37409229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 37409229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladarixin (LDX)
Number of subjects: 76
Study 37409270 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated-care group
Number of subjects: 500
Study 37409270 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 500
Study 37409323 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel (car/pac)
Number of subjects: 103
Study 37409323 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Capecitabine (cis/cap)
Number of subjects: 103
Study 37409464 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 63
Study 37409464 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 63
Study 37409467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 h/night)
Number of subjects: 65
Study 37409467 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (-1.5 h/night)
Number of subjects: 65
Study 37409509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate
Number of subjects: 106
Study 37409565 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade for 3 months
Number of subjects: 34
Study 37409613 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy (monotherapy or combined with chemotherapy)
Number of subjects: 106
Study 37409664 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) left ventricular assist device (LVAD)
Number of subjects: 43
Study 37409757 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine supplementation (2.5 and 5.0 g/d)
Number of subjects: 43
Study 37409757 — intervention group
Group type: COMPARATOR
Intervention: Control (no betaine supplementation)
Number of subjects: 43
Study 37409780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 25
Study 37409817 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP-based management
Number of subjects: 0
Study 37409817 — intervention group
Group type: COMPARATOR
Intervention: Non-ICP-based management
Number of subjects: 0
Study 37409892 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive prenatal testing (NIPT) results suggesting maternal cancer
Number of subjects: 49
Study 37409991 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI
Number of subjects: 1237
Study 37409992 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Transcoronary Pacing Strategy
Number of subjects: 0
Study 37409992 — intervention group
Group type: COMPARATOR
Intervention: Rotational Atherectomy
Number of subjects: 0
Study 37410050 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) cream
Number of subjects: 784
Study 37410050 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) topical solution
Number of subjects: 784
Study 37410050 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 784
Study 37410417 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric service dog placement
Number of subjects: 168
Study 37410421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for primary care (MTPC)
Number of subjects: 0
Study 37410421 — intervention group
Group type: COMPARATOR
Intervention: Low-dose mindfulness comparator (LDC)
Number of subjects: 0
Study 37410465 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified care (physiotherapy treatment tailored for risk category)
Number of subjects: 270
Study 37410465 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified care
Number of subjects: 270
Study 37410465 — intervention group
Group type: COMPARATOR
Intervention: Usual care (determined by general practitioners)
Number of subjects: 270
Study 37410465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study 37410476 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1/PD-1 ligand 1 ICIs alone (control arm)
Number of subjects: 99
Study 37410476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-1 ligand 1 ICIs combined with stereotactic body radiotherapy (experimental arm)
Number of subjects: 99
Study 37410476 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 99
Study 37410476 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 99
Study 37410476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 99
Study 37410518 — intervention group
Group type: EXPERIMENTAL
Intervention: COM-B questionnaire
Number of subjects: 0
Study 37410541 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Cancer Coach app intervention
Number of subjects: 180
Study 37410541 — intervention group
Group type: COMPARATOR
Intervention: Attention control (Springboard Beyond Cancer website)
Number of subjects: 180
Study 37410699 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up HPV test (intervention group)
Number of subjects: 11212
Study 37410699 — intervention group
Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 11212
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication purchased in the informal sector
Number of subjects: 439
Study 37410740 — intervention group
Group type: COMPARATOR
Intervention: Medication purchased in the formal sector
Number of subjects: 439
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic usage in the informal sector
Number of subjects: 439
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from the closest study site
Number of subjects: 439
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Community cohort site inclusion
Number of subjects: 439
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness with general malaise, fever, or headache
Number of subjects: 439
Study 37410740 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound/skin disease
Number of subjects: 439
Study 37411031 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent immunotherapy
Number of subjects: 15
Study 37411039 — intervention group
Group type: EXPERIMENTAL
Intervention: Icenticaftor, a CFTR potentiator
Number of subjects: 0
Study 37411039 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37413896 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Positive Health Programme (PHP) (n = 42)
Number of subjects: 83
Study 37413896 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 41)
Number of subjects: 83
Study 37413939 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (COVID-19 outpatients)
Number of subjects: 29
Study 37413939 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (hospitalized COVID-19 patients)
Number of subjects: 29
Study 37413939 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control group without COVID-19)
Number of subjects: 29
Study 37414012 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) combined with BCMA CAR T cells
Number of subjects: 19
Study 37414060 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI0002h (BCMA-directed CAR T-cell therapy)
Number of subjects: 35
Study 37414062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib maintenance (400 mg orally twice daily)
Number of subjects: 202
Study 37414062 — intervention group
Group type: COMPARATOR
Intervention: Non-maintenance (control)
Number of subjects: 202
Study 37414064 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA bifrontal stimulation for 30 min every weekday for 4 weeks, then two sessions per week for 2 weeks)
Number of subjects: 150
Study 37414064 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (same intervals as active tDCS)
Number of subjects: 150
Study 37414064 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 150
Study 37414064 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 150
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 60 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 80 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 100 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 200 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 30 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: COMPARATOR
Intervention: Pooled placebo
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine 30 mg, 60 mg, 80 mg
Number of subjects: 39
Study 37414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabamiquine (all doses)
Number of subjects: 39
Study 37414069 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 1678
Study 37414069 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 1678
Study 37414071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 109
Study 37414071 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 109
Study 37414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 626
Study 37414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 626
Study 37414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitor (TNFi)
Number of subjects: 626
Study 37414137 — intervention group
Group type: COMPARATOR
Intervention: NSAID use
Number of subjects: 626
Study 37414215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab 200 mg IV followed by 1 year of adjuvant pembrolizumab
Number of subjects: 30
Study 37414422 — intervention group
Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 79
Study 37414440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retreatment using hot snare resection, cold avulsion forceps with adjuvant snare tip soft coagulation, or a combination of the two.
Number of subjects: 213
Study 37414440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy of recurrence
Number of subjects: 213
Study 37414440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 213
Study 37414440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of RRA
Number of subjects: 213
Study 37414460 — intervention group
Group type: COMPARATOR
Intervention: PA (Patient advice)
Number of subjects: 180
Study 37414460 — intervention group
Group type: COMPARATOR
Intervention: PAX (Patient advice plus exercise)
Number of subjects: 180
Study 37414460 — intervention group
Group type: EXPERIMENTAL
Intervention: PAXI (Patient advice plus exercise plus corticosteroid injection)
Number of subjects: 180
Study 37414613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique technique
Number of subjects: 200
Study 37414613 — intervention group
Group type: COMPARATOR
Intervention: AP technique
Number of subjects: 200
Study 37414702 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography (PET/CT) with 296 MBq injection
Number of subjects: 352
Study 37414705 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine-cisplatin (GC)
Number of subjects: 227
Study 37414705 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC)
Number of subjects: 227
Study 37414705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic response (<pT2)
Number of subjects: 227
Study 37414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) plus PD-1 inhibitors (nivolumab or pembrolizumab)
Number of subjects: 20
Study 37414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 20
Study 37414899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (FMT plus PD-1 inhibitors)
Number of subjects: 20
Study 37414923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-based antiretroviral therapy (tenofovir, lamivudine, efavirenz)
Number of subjects: 1288
Study 37415001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg once daily orally)
Number of subjects: 0
Study 37415001 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (7.5 mg orally)
Number of subjects: 0
Study 37415001 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate (75 mg orally)
Number of subjects: 0
Study 37415024 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and Remote Early Warning Score-based notification protocol (CREWS)
Number of subjects: 102
Study 37415048 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) using an inspiratory threshold loading device at 4 cmH2O
Number of subjects: 26
Study 37415100 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 97
Study 37415100 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (11 as primary treatment and 4 during follow-up)
Number of subjects: 97
Study 37415100 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection or platelet rich plasma injection
Number of subjects: 97
Study 37415099 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCap automated double randomization
Number of subjects: 0
Study 37415221 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial parasternal intercostal plane block (SPIP) with standard care
Number of subjects: 254
Study 37415221 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep parasternal intercostal plane block (DPIP) with standard care
Number of subjects: 254
Study 37415221 — intervention group
Group type: COMPARATOR
Intervention: Standard care without regional anesthesia (Control)
Number of subjects: 254
Study 37415223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma protein biomarkers in cases (patients who developed pneumonia)
Number of subjects: 1997
Study 37415223 — intervention group
Group type: COMPARATOR
Intervention: Plasma protein biomarkers in controls (patients who did not develop pneumonia)
Number of subjects: 1997
Study 37415239 — intervention group
Group type: EXPERIMENTAL
Intervention: DZD1516 monotherapy at 250 mg, twice daily (BID)
Number of subjects: 23
Study 37415239 — intervention group
Group type: EXPERIMENTAL
Intervention: DZD1516 monotherapy
Number of subjects: 23
Study 37415239 — intervention group
Group type: EXPERIMENTAL
Intervention: DZD1516
Number of subjects: 23
Study 37415246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lifestyle intervention
Number of subjects: 153
Study 37415246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 37415381 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic stroke work (SW) using integrated pressure-strain myocardial work (MW) software
Number of subjects: 42
Study 37415381 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic wasted work (RVGWW)
Number of subjects: 42
Study 37415503 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 37415503 — intervention group
Group type: COMPARATOR
Intervention: Tirzepatide
Number of subjects: 0
Study 37415648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 90
Study 37415648 — intervention group
Group type: COMPARATOR
Intervention: Combined Therapy (CT) - oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day
Number of subjects: 90
Study 37415648 — intervention group
Group type: COMPARATOR
Intervention: Combined Therapy (CT)
Number of subjects: 90
Study 37415687 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-specific psychotherapeutic program (MSPP)
Number of subjects: 144
Study 37415687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 144
Study 37415687 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 144
Study 37415712 — intervention group
Group type: EXPERIMENTAL
Intervention: Paro robot integrated with usual care
Number of subjects: 20
Study 37415712 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (cognitive stimulation and occupational activities)
Number of subjects: 20
Study 37415845 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day
Number of subjects: 18
Study 37415845 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 18
Study 37415957 — intervention group
Group type: EXPERIMENTAL
Intervention: Before enzyme replacement therapy
Number of subjects: 20
Study 37416926 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA SARS-CoV-2 vaccination-related myocarditis
Number of subjects: 59
Study 37417229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding ACURATE neo (NEO)
Number of subjects: 739